To combat these issues, the last decade has seen the advent of alternate treatment modalities, such as tyrosine kinase inhibitors (TKIs) as a first‐line targeted therapy option in NSCLC patients positive for epidermal growth factor receptor (EGFR) constitutive activating mutations (Hirsch et al, 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.